Wave Life Sciences stock, WVE-007

Wave Life Sciences stock highlights WVE-007 obesity trial progress

Published on 11/17/2026 at 13:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Wave Life Sciences stock follows a company update on WVE-007 Phase 1 findings. The company plans to integrate a maintenance trial with its tirzepatide study.

WVE-007 trial moves forward

  • Wave reported Phase 1 findings for WVE-007 at ObesityWeek 2026, including durable Activin E reductions and preserved lean mass in selected cohorts.
  • Phase 2a monotherapy data are expected in 2027, while a combination trial with tirzepatide is ongoing.
  • Wave plans to integrate its maintenance trial into the ongoing combination study to improve operational efficiency and accelerate data availability.
Wave Life Sciences stock, WVE-007, obesity treatment, RNA medicines, clinical trials, Illustration mit AI erstellt.

Wave Life Sciences said in a November 13, 2026 release that updated Phase 1 findings for WVE-007 continued to support the investigational RNA medicine's potential to reduce fat while preserving lean mass. The company presented the program at ObesityWeek 2026 in Washington, D.C.

Wave said single-dose Activin E reductions in the 240 mg, 400 mg and 600 mg cohorts reached mean maximums of 82%, 84% and 88%, respectively. The company also reported that WVE-007 was generally safe and well tolerated in the Phase 1 portion of the INLIGHT trial, with no discontinuations or drug-related serious adverse events.

In the 240 mg cohort, which had the highest baseline body mass index, Wave said placebo-adjusted reductions in visceral fat, total fat and waist circumference continued to be observed one year after a single dose, while lean mass was preserved. Results from the 600 mg cohort at six months showed reductions in visceral fat and waist circumference, with lean mass preserved and total fat relatively unchanged.

Wave is continuing the Phase 2a portion of INLIGHT in people with higher body mass index and adiposity, with and without type 2 diabetes. The company expects six-month data from that monotherapy study in 2027.

Wave has also started a Phase 2a study comparing WVE-007 with weekly tirzepatide against tirzepatide alone. It plans to integrate a maintenance trial into that ongoing combination study, which the company expects to improve operational efficiency and accelerate the timing of data.

Wave Life Sciences stock traded at 2.64 euros on Lang & Schwarz at 13:39 CET on Tuesday, November 17, 2026.

Wave Life Sciences at a glance

  • Company: Wave Life Sciences, Inc.
  • Ticker: WVE
  • Primary exchange: Nasdaq
  • Lang & Schwarz quote: 2.64 euros at 13:39 CET on November 17, 2026
  • Lead program: WVE-007

For broader US market context, see current Nasdaq Composite market reports.

Wave's clinical focus spans obesity, alpha-1 antitrypsin deficiency and PNPLA3 I148M liver disease through its RNA medicine platform.

Read more company coverage in Wave Life Sciences' release.

Disclaimer...
en | boerse | 70526928 |